Mehdizadeh Mohammad, Ghassemi Alireza, Khakzad Mohammad, Mir Mehrafza, Nekoohesh Leili, Moghadamnia Aliakbar, Bijani Ali, Mehrbakhsh Zahra, Ghanepur Hosein
Department of Oral and Maxillofacial Surgery, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran.
Department of Oral and Maxillofacial Surgery, Shahid Beheshti Hospital, Babol University of Medical Sciences, Babol, Iran.
Aesthetic Plast Surg. 2018 Feb;42(1):246-252. doi: 10.1007/s00266-017-0969-x. Epub 2017 Oct 4.
Dexamethasone and tranexamic acid are used to decrease post-rhinoplasty periorbital edema and ecchymosis. We compared the impact of each medication separately or in combination in this regard.
A prospective, randomized triple-blinded study was undertaken on 60 patients who underwent primary open rhinoplasty. They were divided into four groups: Group D (n = 15) received 8 mg dexamethasone, group T (n = 15) received 10 mg/kg tranexamic acid, group DT (n = 15) received both 8 mg dexamethasone and 10 mg/kg tranexamic acid, and group P (n = 15) received neither medication and served as the placebo control group. The medications were given intravenously (IV) 1 h before and three doses every 8 h postoperatively. Digital photographs were taken on the first, third and seventh postoperative days. One expert examiner blinded to the study evaluated the periorbital edema and ecchymosis on a scale of 0-4. Periorbital edema and ecchymosis were examined in all groups.
In group D, group T and group DT, periorbital edema and ecchymosis ratings were significantly lower compared with the control group (p < 0.01). No statistically significant difference was seen in preventing or decreasing both periorbital edema and ecchymosis among group D, group T and group DT.
Tranexamic acid and dexamethasone, separately or in combination, had similar effects in reducing periorbital edema and ecchymosis in open rhinoplasty. Combined application did not show a significantly higher beneficial effect in this regard.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
地塞米松和氨甲环酸用于减轻鼻整形术后眶周水肿和瘀斑。我们比较了每种药物单独使用或联合使用在这方面的影响。
对60例行初次开放式鼻整形术的患者进行了一项前瞻性、随机、三盲研究。他们被分为四组:D组(n = 15)接受8毫克地塞米松,T组(n = 15)接受10毫克/千克氨甲环酸,DT组(n = 15)接受8毫克地塞米松和10毫克/千克氨甲环酸,P组(n = 15)不接受任何药物,作为安慰剂对照组。药物在术前1小时静脉注射,术后每8小时注射三剂。在术后第1天、第3天和第7天拍摄数码照片。一位对研究不知情的专家检查者以0-4分的量表评估眶周水肿和瘀斑。对所有组的眶周水肿和瘀斑进行了检查。
与对照组相比,D组、T组和DT组的眶周水肿和瘀斑评分显著更低(p < 0.01)。D组、T组和DT组在预防或减轻眶周水肿和瘀斑方面未见统计学显著差异。
氨甲环酸和地塞米松单独使用或联合使用在减轻开放式鼻整形术中的眶周水肿和瘀斑方面具有相似的效果。联合应用在这方面未显示出明显更高的有益效果。
证据级别III:本刊要求作者为每篇文章指定证据级别。有关这些循证医学评级的完整描述,请参阅目录或在线作者指南www.springer.com/00266 。